Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (8432)	5/20/2003 1:15:26 PM
From: Icebrg	Read Replies (1) \| Respond to of 52153

Peter >> Note incidentally that there is also quite a bit of work on anti-VEGF in macular degeneration as well as cancer. For example, Eyetech recently announced a very significant partnership with Pfizer in this area. (Incidentally their drug, Macugen, was licensed from GILD). Also I think RNAI has a similar program.>> Yes, and Genentech is about to start their own - what they hope will be pivotal - phase III programs with rhuFab which is an Avastin fragment. QLT will come under pressure. Especially as there doesn't appear to be much hope left for Tariquidar. Erik